Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Most Profitable Biotech Stocks to Invest in Now

Page 1 of 9

In this article, we will look at the 10 Most Profitable Biotech Stocks to Invest in Now.

Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s ‘Power Lunch’ on March 5 to talk about investing in biotech and the oversaturation in the sector. His motto for investing in the biotech sector is stock picking, as he stated that “stock picking is the only way to make money in biotech.”

Holz further said that the denominator of biotech stocks in the public markets comes to 700 to 800, depending on the day. A quarter of those have enterprise values in negative territories, which translates to the fact that investors, and even the companies themselves, have in some respects exhausted options.

READ ALSO: 10 Best Strong Buy Healthcare Stocks to Buy Now and 11 Best Shipping and Container Stocks to Invest in Now

There are thousands of biotech companies all competing against one another for limited market and revenue opportunities. According to Holz, venture funds should stop creating so many new companies that end up superseding each other in a few years.

With these trends in view, let’s look at the most profitable biotech stocks to invest in now.

A wide shot of a biotech lab, with scientists wearing lab coats and conducting research.

Our Methodology

We used Finviz to make a list of profitable biotech stocks (with a TTM net income over $100 million) and selected the top 10 with the highest number of hedge fund holders as of Q1 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund holders.

Note: All data was sourced on July 23.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

10 Most Profitable Biotech Stocks to Invest in Now

10. Genmab A/S (NASDAQ:GMAB)

TTM Net Income: $1.14 billion

Number of Hedge Fund Holders: 20

Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to invest in now. In a report released on July 14, Yaron Werber from TD Cowen maintained a Hold rating on Genmab A/S (NASDAQ:GMAB) without a price target.

In other news, Genmab A/S (NASDAQ:GMAB) reported on July 16 that net sales of DARZALEX totaled $3.539 billion in Q2 2025, with net trade sales of $ 2.017 billion in the US and $1.521 billion in the rest of the world.

Genmab A/S (NASDAQ:GMAB) receives royalties on the global net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Johnson & Johnson for the manufacturing, development, and commercialization of daratumumab.

Genmab A/S (NASDAQ:GMAB) is an international biotechnology company that develops human antibody therapeutics for the treatment of cancer and other diseases.

Its product pipeline includes DARZALEX to treat certain indications of multiple myeloma, TEPEZZA for the treatment of thyroid eye disease, and Arzerra to treat certain indications of chronic lymphocytic leukemia.

9. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

TTM Net Income: $485.36 million

Number of Hedge Fund Holders: 31

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to invest in now. On July 16, Morgan Stanley analyst Sean Laaman maintained a neutral stance on Halozyme Therapeutics, Inc. (NASDAQ:HALO), giving the stock a Hold rating with a $62 price target.

The analyst reasoned that one of the key concerns regarding Halozyme Therapeutics, Inc. (NASDAQ:HALO) is the uncertainty around the CMS draft pricing guidance, as it could potentially affect the pricing negotiations for the company’s combination products.

He stated that this draft guidance may be a matter of concern for Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) long-term revenues, which holds especially true if the products are not exempt from the price negotiations anticipated to take effect in 2028.

Laaman further reasoned that while Halozyme Therapeutics, Inc. (NASDAQ:HALO) raised its financial guidance for 2025 with higher partner orders and royalty revenues, it is still unclear how regulatory updates would affect these estimates.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology. They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.

Page 1 of 9

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!